PULM
vs
S&P 500
PULM
S&P 500
Over the past 12 months, PULM has underperformed S&P 500, delivering a return of -75% compared to the S&P 500's +12% growth.
Stocks Performance
PULM vs S&P 500
Performance Gap
PULM vs S&P 500
Performance By Year
PULM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Pulmatrix Inc
Glance View
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The company is headquartered in Lexington, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2014-03-21. The company designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled small particles easily respirable and emitted (iSPERSE), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE’s lead development program, Pulmazole is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. PUR1800 is developing for the treatment of acute exacerbations of chronic obstructive pulmonary disease and PUR3100 is developing for the treatment of acute migraine.
